NASDAQ$SRRK
Scholar Rock Holding Corporation · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Scholar Rock reported positive topline data from pivotal Phase 3 SAPPHIRE trial and completed $345 million public offering.
Scholar Rock reported positive topline data from the Phase 3 SAPPHIRE trial of apitegromab in SMA patients and completed enrollment in the Phase 2 EMBRAZE trial for apitegromab in obesity. The company also completed an upsized $345 million public offering. Net loss for the quarter was $64.5 million, or $0.66 per share.
- Reported positive topline data from pivotal Phase 3 SAPPHIRE trial evaluating apitegromab in patients with Spinal Muscular Atrophy (SMA), achieving primary endpoint.
- On track to submit a U.S. Biologics License Application (BLA) and European Union marketing authorisation application (MAA) in 1Q 2025.
- Phase 2 EMBRAZE trial enrollment completed for apitegromab in obesity with topline data expected in 2Q 2025.
- Successful completion of upsized $345 million public offering to fund planned commercial launch in SMA and continue to advance priority programs.
Headline financials
Revenue & EPS history
Scholar Rock · Revenue · Quarterly
$0
Forward guidance
Scholar Rock is advancing towards its first commercial launch in Q4 2025, aiming to obtain approval for apitegromab and deliver it to patients with SMA, while also progressing its portfolio of myostatin inhibition programs.
Tailwinds
- Plans to submit a BLA and MAA in the first quarter of 2025 based on positive SAPPHIRE trial results.
- Preparing for the commercial launch of apitegromab to deliver transformative benefits to children and adults living with SMA, if approved.
- Expects to report initial data from the fully enrolled Phase 2 EMBRAZE trial in the second quarter of next year.
- Plans to file an IND for SRK-439 for the treatment of obesity in 2025.
- Advancing mission from a position of strength, supported by a recent public offering on the heels of successful SAPPHIRE data.
Headwinds
- The efficacy and safety of apitegromab, SRK-181, and SRK-439 have not been established.
- Apitegromab, SRK-181, and SRK-439 have not been approved for any use by the FDA or any other regulatory agency.
- Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
- Dependence on third parties for development and manufacture of product candidates, including to supply any clinical trials.
- Ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+3.6%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+3.5%
Avg return
30 days after
58%
18 / 31 earnings
Positive
+24.6%
Q4 2023
Best reaction
-7.6%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.4% | +4.4% | -6.1% | |
| Q4 2025 | +2.0% | +4.2% | +15.0% | |
| Q3 2025 | +24.1% | +32.0% | +55.9% | |
| Q2 2025 | -6.1% | -14.9% | -15.1% | |
| Q1 2025 | -2.6% | -3.9% | +3.3% | |
| Q4 2024 | -2.9% | +0.2% | -11.3% | |
| Q3 2024 | -2.7% | -5.9% | +48.0% | |
| Q1 2024 | -3.7% | -11.4% | -37.4% | |
| Q4 2023 | +24.6% | +24.2% | +5.7% | |
| Q3 2023 | -1.8% | -17.5% | +44.2% | |
| Q2 2023 | +6.3% | +11.6% | -3.6% | |
| Q1 2023 | +4.4% | -0.1% | -13.6% | |
| Q4 2022 | +7.2% | -1.9% | -15.7% | |
| Q3 2022 | +10.9% | +0.2% | +1.5% | |
| Q2 2022 | +6.9% | +32.9% | +5.2% | |
| Q1 2022 | +7.3% | -5.2% | -9.7% | |
| Q4 2021 | -5.1% | -9.5% | -8.6% | |
| Q3 2021 | +16.8% | +24.2% | -10.4% | |
| Q2 2021 | +4.8% | +7.5% | +4.6% | |
| Q1 2021 | -2.4% | +0.1% | +10.6% | |
| Q4 2020 | +16.8% | +21.4% | -40.2% | |
| Q3 2020 | -1.0% | +2.8% | +7.7% | |
| Q2 2020 | +3.9% | -4.1% | +5.0% | |
| Q1 2020 | -4.8% | +6.9% | +2.2% | |
| Q4 2019 | +4.3% | +9.4% | -1.1% | |
| Q3 2019 | -7.6% | -14.5% | +17.0% | |
| Q2 2019 | +0.8% | +11.9% | +19.4% | |
| Q1 2019 | +6.2% | +8.6% | -4.9% | |
| Q4 2018 | +9.8% | +2.3% | -7.4% | |
| Q3 2018 | +2.0% | -10.0% | -1.6% | |
| Q2 2018 | -6.7% | -11.9% | +51.0% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro